December 21, 2014 1:28 AM ET


Company Overview of Excelimmune, Inc.

Company Overview

Excelimmune, Inc., a biopharmaceutical company, engages in the development of human recombinant polyclonal antibodies for therapeutic use. The company focuses on the treatment of infections caused by staphylococcus aureus, including the drug resistant superbug, methicillin-resistant staphylococcus aureus. It offers a platform for developing human recombinant polyclonal antibody therapeutics for therapeutic applications, such as the treatment of infectious diseases, protein diseases, and cancer. Excelimmune, Inc. was founded in 2006 and is based in Woburn, Massachusetts.

12-B Cabot Road

Woburn, MA 01801

United States

Founded in 2006





Key Executives for Excelimmune, Inc.

Chief Executive Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
BioE Corporation United States
Embryome Sciences, Inc. United States
HemoShear, LLC United States
Dynamis Therapeutics, Inc. United States
Sutter Instrument Company United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Excelimmune, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at